Literature DB >> 19307060

Role of rat sensory neuron-specific receptor (rSNSR1) in inflammatory pain: contribution of TRPV1 to SNSR signaling in the pain pathway.

Christian Ndong1, Amynah Pradhan, Carole Puma, Jean-Pierre Morello, Cyrla Hoffert, Thierry Groblewski, Dajan O'Donnell, Jennifer M A Laird.   

Abstract

Sensory neuron-specific receptors (SNSRs) belong to a large family of GPCRs, known as Mrgs (Mas-related genes), many of which are preferentially expressed in primary afferent nociceptors. Selective SNSR agonists produce pain-like behaviors in rats, showing that SNSR activation is sufficient to produce pain. However, it is unknown whether SNSR activation is necessary for pain either in the normal condition or in pathological pain states. Here we used small interfering RNA (siRNA) to acutely knockdown rat SNSR1 and test the hypothesis that this receptor mediates pain responses. Administration of siRNA to the lumbar spinal cord in rats dose-dependently knocked down rSNSR1 mRNA and protein and abolished heat hyperalgesia evoked by intradermal administration of specific rSNSR1 agonists. In rats with levels of rSNSR1 knockdown sufficient to block responses to the SNSR1 agonists, there was no effect on normal pain responses, but there was a significant reduction of heat hyperalgesia in an inflammatory pain model (Complete Freund's Adjuvant), supporting a role for rSNSR1 in inflammatory pain. Further in vivo studies revealed that SNSR1 knockdown had no effect on responses to intradermal capsaicin, a selective TRPV1 agonist. In contrast, a selective TRPV1 antagonist abolished heat hyperalgesia produced by an SNSR agonist, suggesting that TRPV1 receptors mediate rSNSR1-evoked responses. We also found that rSNSR1-like immunoreactivity, like TRPV1, is localized in the superficial dorsal horn of the spinal cord. We propose that rSNSR1 represents a new member of the receptors expressed on chemosensitive nociceptors responsible for detecting the "inflammatory soup" of mediators generated by tissue damage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19307060     DOI: 10.1016/j.pain.2009.02.010

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  6 in total

1.  Mas-related G-protein-coupled receptors inhibit pathological pain in mice.

Authors:  Yun Guan; Qin Liu; Zongxiang Tang; Srinivasa N Raja; David J Anderson; Xinzhong Dong
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-19       Impact factor: 11.205

Review 2.  Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions.

Authors:  Wendy M Walwyn; Karen A Miotto; Christopher J Evans
Journal:  Drug Alcohol Depend       Date:  2010-02-25       Impact factor: 4.492

3.  MrgC agonism at central terminals of primary sensory neurons inhibits neuropathic pain.

Authors:  Shao-Qiu He; Zhe Li; Yu-Xia Chu; Liang Han; Qian Xu; Man Li; Fei Yang; Qin Liu; Zongxiang Tang; Yun Wang; Niyada Hin; Takashi Tsukamoto; Barbara Slusher; Vinod Tiwari; Ronen Shechter; Feng Wei; Srinivasa N Raja; Xinzhong Dong; Yun Guan
Journal:  Pain       Date:  2013-12-11       Impact factor: 6.961

4.  Effect of Mas-related gene (Mrg) receptors on hyperalgesia in rats with CFA-induced inflammation via direct and indirect mechanisms.

Authors:  Jianping Jiang; Dongmei Wang; Xiaolong Zhou; Yuping Huo; Tingjun Chen; Fenjuan Hu; Rémi Quirion; Yanguo Hong
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

5.  Atypical signaling and functional desensitization response of MAS receptor to peptide ligands.

Authors:  Kalyan C Tirupula; Russell Desnoyer; Robert C Speth; Sadashiva S Karnik
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

6.  Involvement of MrgprC in Electroacupuncture Analgesia for Attenuating CFA-Induced Thermal Hyperalgesia by Suppressing the TRPV1 Pathway.

Authors:  Ying-Jun Liu; Xiao-Xi Lin; Jian-Qiao Fang; Fang Fang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-12       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.